Gris-Oliver et al. demonstrated that PI3K pathway activation induces resistance to eribulin in HER2-breast cancer patients, while PI3K inhibits apoptosis and reduces drug efficacy by promoting P21 [37]. This evidence concerns the gene ERBB2 and breast carcinoma.